Private EquityScreenerRefer

MARKET INSIGHTS

  • EventsNEWPrivate market milestones
  • NewsPrecize daily pulse
  • BlogsIn-depth articles and opinions

GUIDES

Explore Now
  • Unlisted SharesStep-by-step · KYC
  • BuyingStep-by-step · KYC
  • SellingExit in 24 - 48 hours
  • Pre-IPOReturns · risks · case studies
  • Tax GuideBudget 2026 changes
  1. Home
  2. Unlisted share news
  3. Naspers, Temasek get CCI approval to purchase stakes in PharmEasy

Naspers, Temasek get CCI approval to purchase stakes in PharmEasy

30 Jan 2024

Add as preferred source
Key Takeaways

  • CCI-Approved Expansion:

    • PharmEasy's stake acquisitions by reputable entities receive CCI endorsement, affirming investor confidence.

    • Naspers Ventures BV and Temasek-led consortium's involvement signifies strong backing for PharmEasy's strategic growth and enhanced healthcare services.

  • CCI-Approved Expansion:

    • PharmEasy's stake acquisitions by reputable entities receive CCI endorsement, affirming investor confidence.

    • Naspers Ventures BV and Temasek-led consortium's involvement signifies strong backing for PharmEasy's strategic growth and enhanced healthcare services.

pharmeasy unlisted shares

API Holdings (Pharmeasy)

-8.09%

Expert Analysis

PharmEasy Secures CCI Approval for Strategic Stake Acquisitions by Naspers and Temasek-Led Consortium, Reinforcing Investor Confidence in Healthcare Expansion

Expert Analysis:

  • Stakeholder Confidence:

    • PharmEasy gains CCI clearance for stake acquisitions by Naspers Group and Temasek.

    • Naspers Ventures BV, a Prosus subsidiary, plans additional API Holdings shares acquisition via a rights issue.

  • Diverse Investor Support:

    • Temasek, CDPQ Private Equity Asia, DBS Group, and Goldman Sachs India Alternative Investment Trust approved for API Holdings stakes.

    • Proposed transactions involve convertible preference shares (CCPS) subscriptions by various entities, signaling broad investor interest.

  • Strategic Alliances:

    • MacRitchie Investments (Temasek subsidiary) and EvolutionX (DBS-Temasek joint venture) participate in CCPS subscription.

    • Goldman Sachs India AIF Schemes underline the diverse financial backing PharmEasy attracts.

Publisher:Mint